Related Experiment Video
Updated: Aug 6, 2025
02:35
Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
Published on: March 22, 2024
903
Quantitative expression evaluation of PRAME gene in osteosarcoma
Aline Satuki Kuruwitage Ishikawa1, Francine Tesser-Gamba1,2, Antônio Sérgio Petrilli1,3
1Pediatric Oncology Institute (IOP/GRAACC), Federal University of Sao Paulo, Sao Paulo, SP, Brazil.
Molecular Biology Reports
|March 16, 2023
Summary
Quantitative analysis of Preferentially Expressed Antigen in Melanoma (PRAME) gene expression in osteosarcoma (OS) showed increased levels but no correlation with patient groups or disease progression. PRAME remains a promising biomarker for potential early metastasis detection in OS.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Previous qualitative studies indicated Preferentially Expressed Antigen in Melanoma (PRAME) gene expression in 68% of osteosarcoma (OS) samples.
- This study aimed to quantitatively assess PRAME gene expression in distinct OS patient cohorts.
Purpose of the Study:
- To quantitatively investigate PRAME gene expression levels in osteosarcoma patient groups.
- To determine any correlation between PRAME expression and clinical parameters or disease evolution.
Main Methods:
- Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) was used to measure PRAME gene expression.
- Data from 61 osteosarcoma samples across three patient groups (age, disease progression, remission) were analyzed.
- Clinical data were collected from patient medical charts.
Main Results:
- PRAME gene expression was elevated across all osteosarcoma samples, exhibiting significant variation.
- No statistical differences in PRAME expression were observed between the distinct patient groups.
- No correlation was found between PRAME gene expression levels and collected clinical data or disease evolution.
Conclusions:
- Quantitative PRAME gene expression analysis in osteosarcoma did not provide additional information beyond qualitative findings.
- PRAME gene expression levels do not correlate with disease evolution in osteosarcoma patients.
- PRAME is validated as a potential biomarker for osteosarcoma, possibly aiding in early metastasis detection and improving patient survival.
